Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Other Accumulated Expenses (2021 - 2025)

Pliant Therapeutics (PLRX) has disclosed Other Accumulated Expenses for 5 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 66.55% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 66.55% year-over-year, with the annual reading at $4.8 million for FY2025, 66.55% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $4.8 million at Pliant Therapeutics, down from $7.8 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $23.0 million in Q3 2024, with the low at $4.8 million in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $13.4 million, with a median of $14.0 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 91.17% in 2022, then crashed 66.55% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $5.9 million in 2021, then soared by 91.17% to $11.2 million in 2022, then increased by 11.04% to $12.5 million in 2023, then increased by 15.31% to $14.4 million in 2024, then plummeted by 66.55% to $4.8 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $4.8 million, $7.8 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.